We welcome the European Commission's proposal to invest €100 billion on research in
the Horizon Europe programme from 2021 to 2027 [
[1]
,
]. We hope the detailed proposals for each policy area will consider the interest
of citizens first and foremost and aim at equitable welfare for all. In the medical
area – in which we work - we are still far from this goal at present. Besides those
promoted and funded by industry even clinical trials supported by EU public funds
often fail to address patient-centered questions and to answer them with reliable
methods. Most of these studies, for instance, appear to promote new medicines more
than answering important therapeutic questions. As commercial studies, they often
use placebo as a control, or a non-inferiority design when an active control is in
fact adopted. They often aim at surrogate outcome measures rather than seeing longer
and/or better lives which is what matters to patients and public health professionals
in the end.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- €100-billion budget proposed for Europe's next big research programme.Nature. 2018; 557: 150https://doi.org/10.1038/d41586-018-05105-0
- Science. 2018; 360: 583
Article info
Publication history
Published online: July 15, 2018
Accepted:
July 9,
2018
Received:
July 6,
2018
Identification
Copyright
© 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
